OBJECTIVE: To explore the association between expression of ADAM17 and cetuximad resistance in human colorectal cancer SW480 cells. METHODS: The expression of ADAM17 was detected using Western blotting in different human colorectal cancer cell lines, and the cells highly expressing ADAM17 were selected as the target cells. SW480 cells were transfected with ADAM17-siRNA 1 and ADAM17-siRNA 2 and the changes in the expression of ADAM17 protein were detected using Western blotting. SW480 cells were exposed to cetuximad for 24 h and the cell apoptosis was analyzed using flow cytometry. Transwell assay was used to examine the migration ability of SW480 cells with different expression levels of ADAM17; Western blotting was used to analyze the changes in the expressions of AKT signaling pathway-related proteins in the treated cells. RESULTS: The baseline expressions of ADAM17 were significantly higher in SW480 cells than in the other human colorectal cancer cell lines tested (P < 0.05). Both ADAM17-siRNA 1 and 2 effectively reduced the expression of ADAM17 protein in SW480 cells. Knockdown of ADAM17 with siRNA 1 significantly increased the sensitivity of SW480 cells to tocetuximad (P < 0.05), obviously inhibited the cell proliferation, migration and invasion, and significantly reduced the expressions of p-EGFR and p-AKT in the cells (P < 0.001). CONCLUSIONS: ADAM17 knockdown obviously inhibits EGFR-AKT signaling pathway and increases the sensitivity of SW480 cells to tocetuximad.
OBJECTIVE: To explore the association between expression of ADAM17 and cetuximad resistance in humancolorectal cancer SW480 cells. METHODS: The expression of ADAM17 was detected using Western blotting in different humancolorectal cancer cell lines, and the cells highly expressing ADAM17 were selected as the target cells. SW480 cells were transfected with ADAM17-siRNA 1 and ADAM17-siRNA 2 and the changes in the expression of ADAM17 protein were detected using Western blotting. SW480 cells were exposed to cetuximad for 24 h and the cell apoptosis was analyzed using flow cytometry. Transwell assay was used to examine the migration ability of SW480 cells with different expression levels of ADAM17; Western blotting was used to analyze the changes in the expressions of AKT signaling pathway-related proteins in the treated cells. RESULTS: The baseline expressions of ADAM17 were significantly higher in SW480 cells than in the other humancolorectal cancer cell lines tested (P &lt; 0.05). Both ADAM17-siRNA 1 and 2 effectively reduced the expression of ADAM17 protein in SW480 cells. Knockdown of ADAM17 with siRNA 1 significantly increased the sensitivity of SW480 cells to tocetuximad (P &lt; 0.05), obviously inhibited the cell proliferation, migration and invasion, and significantly reduced the expressions of p-EGFR and p-AKT in the cells (P &lt; 0.001). CONCLUSIONS:ADAM17 knockdown obviously inhibits EGFR-AKT signaling pathway and increases the sensitivity of SW480 cells to tocetuximad.
Entities:
Keywords:
ADAM17; cetuximad; drug resistance; human colorectal cancer
Authors: Valeria Musella; Filippo Pietrantonio; Eleonora Di Buduo; Roberto Iacovelli; Antonia Martinetti; Elisa Sottotetti; Ilaria Bossi; Claudia Maggi; Maria Di Bartolomeo; Filippo de Braud; Maria Grazia Daidone; Vera Cappelletti Journal: Int J Cancer Date: 2015-03-04 Impact factor: 7.396
Authors: Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Alberto F Sobrero; Joan Maurel; Louis Fehrenbacher; Werner Scheithauer; Yousif A Abubakr; Manfred P Lutz; M Eugenia Vega-Villegas; Cathy Eng; Ernst U Steinhauer; Jana Prausova; Heinz-Josef Lenz; Christophe Borg; Gary Middleton; Hendrik Kröning; Gabriele Luppi; Oliver Kisker; Angela Zubel; Christiane Langer; Justin Kopit; Howard A Burris Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg Journal: Br J Cancer Date: 2007-03-20 Impact factor: 7.640
Authors: A Szpechcinski; J Chorostowska-Wynimko; R Struniawski; W Kupis; P Rudzinski; R Langfort; E Puscinska; P Bielen; P Sliwinski; T Orlowski Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Simon A Hawley; Fiona A Ross; Graeme J Gowans; Priyanka Tibarewal; Nicholas R Leslie; D Grahame Hardie Journal: Biochem J Date: 2014-04-15 Impact factor: 3.857